Neogen to Release Q3 Earnings on April 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy NEOG?
Source: Newsfilter
- Earnings Release Schedule: Neogen® Corporation will issue its third-quarter earnings report before the market opens on April 9, 2026, showcasing the latest financial and business performance updates, which are expected to provide investors with critical performance metrics and future outlook.
- Conference Call Details: Executives will host a webcast and conference call at 8:00 a.m. Eastern Time on the same morning, with investors able to join by dialing the toll-free number 888-660-6264 for North America or 646-517-3975 internationally, using Conference ID 70064#, ensuring timely access to key information for investors.
- Replay Access: A replay of the conference call and webcast will be available shortly after the conclusion of the call, accessible by dialing 877-674-7070 (North America) or 416-764-8692 (International) with the same passcode 70064#, providing convenience for investors who could not participate live.
- Company Mission and Vision: Neogen is committed to advancing global food security and animal well-being through scientific and technological advancements, having established a strong network of scientists and technical experts in over 140 countries, aiming to deliver optimized products and technology to reinforce its market leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEOG
Wall Street analysts forecast NEOG stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 8.910
Low
6.50
Averages
8.17
High
10.00
Current: 8.910
Low
6.50
Averages
8.17
High
10.00
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neogen to Release Q3 Earnings on April 9, 2026
- Earnings Release Schedule: Neogen® Corporation will issue its third-quarter earnings report before the market opens on April 9, 2026, showcasing the latest financial and business performance updates, which are expected to provide investors with critical performance metrics and future outlook.
- Conference Call Details: Executives will host a webcast and conference call at 8:00 a.m. Eastern Time on the same morning, with investors able to join by dialing the toll-free number 888-660-6264 for North America or 646-517-3975 internationally, using Conference ID 70064#, ensuring timely access to key information for investors.
- Replay Access: A replay of the conference call and webcast will be available shortly after the conclusion of the call, accessible by dialing 877-674-7070 (North America) or 416-764-8692 (International) with the same passcode 70064#, providing convenience for investors who could not participate live.
- Company Mission and Vision: Neogen is committed to advancing global food security and animal well-being through scientific and technological advancements, having established a strong network of scientists and technical experts in over 140 countries, aiming to deliver optimized products and technology to reinforce its market leadership.
See More
Neogen Corp Shares Enter Oversold Territory
- Oversold Signal: Neogen Corp (Ticker: NEOG) saw its RSI drop to 28.7 during Monday's trading, indicating the stock has entered oversold territory, suggesting that recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
- Price Fluctuation: NEOG shares hit a low of $9.145, with the current trading price at $9.43, fluctuating between a 52-week low of $3.8701 and a high of $11.425, reflecting changing market sentiment towards the stock.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, NEOG's 28.7 RSI indicates relative weakness, potentially attracting investors looking for a rebound.
- Investor Sentiment: Despite the current price slump, the oversold signal may lead investors to reassess NEOG's value, especially after significant price declines, which could create buying opportunities.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
Neogen Corporation Initiates Nationwide Recall of HYCOAT Product
- Product Recall: Neogen Corporation has initiated a voluntary recall of all unexpired lots of its HYCOAT Hyaluronate Sodium Sterile Solution due to identified microbial contamination in certain batches, impacting its use for topical wound management in dogs, cats, and horses.
- Adverse Event Reports: The company received several adverse event reports following intra-articular injections in horses, a use inconsistent with the product's labeling, although no adverse events were reported when used as directed, highlighting the risks associated with improper use.
- Infection Risk Warning: Neogen warned that affected products should no longer be considered sterile, posing an infection risk particularly if injected into joints or used topically in surgical wounds, burns, ulcers, and autograft procedures.
- Stock Price Reaction: According to Benzinga Pro data, NEOG stock fell 2.80% to $10.06 in the last check on Thursday, reflecting the market's negative response to the recall event.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain 10 mL/50 mg vials, which poses a risk of infection in animals and could damage the company's reputation.
- Adverse Event Reports: The company has received multiple reports of adverse events in horses following intraarticular injections, although no issues have been reported when used as intended, highlighting the risks associated with improper use of the product.
- Collaboration with FDA: Neogen is proactively working with the FDA to investigate the issue and is notifying distributors and customers to ensure a smooth recall process, aiming to mitigate potential legal and financial risks.
- Customer Support: The company is providing a customer support hotline to assist with recall procedures, demonstrating its commitment to customer safety, which may also impact future sales and market trust.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination found in certain batches, involving both 2mL/20mg and 10mL/50mg vials, demonstrating the company's commitment to product safety.
- Adverse Event Reports: Following intraarticular injections in horses, Neogen received multiple reports of adverse events, although no issues were reported when used as intended, indicating potential serious consequences from improper use that could impact the company's reputation.
- Collaboration with FDA: Neogen is proactively working with the FDA on this recall and is notifying distributors and direct customers via email to ensure the safe return of all recalled products, reflecting the company's commitment to compliance and safety.
- Customer Support: The company provides detailed recall information and support channels, including phone and email, ensuring customers can smoothly return products and address related issues, highlighting Neogen's focus on customer service.
See More
Neogen to Release Q3 Earnings on April 9, 2026
- Earnings Release Schedule: Neogen® Corporation will issue its third-quarter earnings report before the market opens on April 9, 2026, showcasing the latest financial and business performance updates, which are expected to provide investors with critical performance metrics and future outlook.
- Conference Call Details: Executives will host a webcast and conference call at 8:00 a.m. Eastern Time on the same morning, with investors able to join by dialing the toll-free number 888-660-6264 for North America or 646-517-3975 internationally, using Conference ID 70064#, ensuring timely access to key information for investors.
- Replay Access: A replay of the conference call and webcast will be available shortly after the conclusion of the call, accessible by dialing 877-674-7070 (North America) or 416-764-8692 (International) with the same passcode 70064#, providing convenience for investors who could not participate live.
- Company Mission and Vision: Neogen is committed to advancing global food security and animal well-being through scientific and technological advancements, having established a strong network of scientists and technical experts in over 140 countries, aiming to deliver optimized products and technology to reinforce its market leadership.
See More
Neogen Corp Shares Enter Oversold Territory
- Oversold Signal: Neogen Corp (Ticker: NEOG) saw its RSI drop to 28.7 during Monday's trading, indicating the stock has entered oversold territory, suggesting that recent heavy selling may be exhausting, prompting investors to look for buying opportunities.
- Price Fluctuation: NEOG shares hit a low of $9.145, with the current trading price at $9.43, fluctuating between a 52-week low of $3.8701 and a high of $11.425, reflecting changing market sentiment towards the stock.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, NEOG's 28.7 RSI indicates relative weakness, potentially attracting investors looking for a rebound.
- Investor Sentiment: Despite the current price slump, the oversold signal may lead investors to reassess NEOG's value, especially after significant price declines, which could create buying opportunities.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
Neogen Corporation Initiates Nationwide Recall of HYCOAT Product
- Product Recall: Neogen Corporation has initiated a voluntary recall of all unexpired lots of its HYCOAT Hyaluronate Sodium Sterile Solution due to identified microbial contamination in certain batches, impacting its use for topical wound management in dogs, cats, and horses.
- Adverse Event Reports: The company received several adverse event reports following intra-articular injections in horses, a use inconsistent with the product's labeling, although no adverse events were reported when used as directed, highlighting the risks associated with improper use.
- Infection Risk Warning: Neogen warned that affected products should no longer be considered sterile, posing an infection risk particularly if injected into joints or used topically in surgical wounds, burns, ulcers, and autograft procedures.
- Stock Price Reaction: According to Benzinga Pro data, NEOG stock fell 2.80% to $10.06 in the last check on Thursday, reflecting the market's negative response to the recall event.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain 10 mL/50 mg vials, which poses a risk of infection in animals and could damage the company's reputation.
- Adverse Event Reports: The company has received multiple reports of adverse events in horses following intraarticular injections, although no issues have been reported when used as intended, highlighting the risks associated with improper use of the product.
- Collaboration with FDA: Neogen is proactively working with the FDA to investigate the issue and is notifying distributors and customers to ensure a smooth recall process, aiming to mitigate potential legal and financial risks.
- Customer Support: The company is providing a customer support hotline to assist with recall procedures, demonstrating its commitment to customer safety, which may also impact future sales and market trust.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination found in certain batches, involving both 2mL/20mg and 10mL/50mg vials, demonstrating the company's commitment to product safety.
- Adverse Event Reports: Following intraarticular injections in horses, Neogen received multiple reports of adverse events, although no issues were reported when used as intended, indicating potential serious consequences from improper use that could impact the company's reputation.
- Collaboration with FDA: Neogen is proactively working with the FDA on this recall and is notifying distributors and direct customers via email to ensure the safe return of all recalled products, reflecting the company's commitment to compliance and safety.
- Customer Support: The company provides detailed recall information and support channels, including phone and email, ensuring customers can smoothly return products and address related issues, highlighting Neogen's focus on customer service.
See More
